esports trophy
Hillenbrand Declares First Quarter Dividend of $0.225 Per ShareGenetic Testing Market Growth Outlook by 2031 Bio-Rad Laboratories, F. Hoffmann-La Roche, Myriad Genetics, QIAGEN, Quest DiagnosticsPlanetarium Labs Launches Immortal Rising 2 Path of Ascension Play 2 Airdrop Pre-Registration at YGG Play Summit'Bruce Willis in the Sixth Sense': Bush adviser says Hegseth doesn't know nomination died
Thousands of drivers born before 1963 face £1,000 fine due to Highway Code law
To learn more about HereHear, please visit: https://www.youtube.com/watch?v=ngU32WgiWf4 "HereHear is here in the US, and I am truly grateful to the Berkeley Skydeck IPP Program for recognizing its potential," noted Lynia Huang , Bamboo Technology's CEO. "As important as mental health has become in recent years, there is a shortage of mental health providers and access to support is low — and HereHear is paving the way for AI to bridge that gap as a first line of defense." A growing case for incorporating AI into mental healthcare With data showing that the US is in a mental health crisis, the CDC recently noted a dire need for public health initiatives that create environments centered around mental health. Specific to the workplace, the Society for Human Resource Management's Employee Mental Health in 2024 Research Series found that 44% of US employees feel burned out at work. The combination of a shortage of mental health providers in the US with the flourishing capabilities of AI builds a strong case for the technology to be deployed in the form of human-guided mental health solutions. HereHear's YangYang: A personalized 3D virtual therapist As organizations seek out ways to empower team members to take better care of their mental health, AI is increasingly emerging as a solution for on-demand, personalized support. Offering a more engaging interaction than chatbots, HereHear's 3D virtual therapist YangYang was launched in January 2024 and offers: Sophisticated vocal and emotional analysis: Aligned with professional assessment scales, it analyzes voice features in 30 seconds to detect levels of stress, depression and happiness, assessing both verbal and nonverbal cues. Broad accessibility : Multiple languages and real-time, personalized support Powered by AI and deep learning: Continuously learns from patient interaction YangYang has already been implemented in several therapy clinics and has helped 70% of users improve stress and depression levels by 25% within 3 months. Taking the form of a sheep further distinguishes her — this functions both to provide a 'cute' aspect lending to the warm, healing emotional support she provides, while also helping users who are struggling emotionally to keep in perspective that their interactions are ultimately not with a human. Bringing success in Taiwan to the US market Bamboo Technology's acceptance into the Berkeley Skydeck IPP Program is a major accomplishment as the platform seeks to enter the US market. Batch 19 has only 117 startups out of around 2300 applications, and the program will support HereHear to develop, pilot and launch, as well as to pitch for funding. The company aims to target the app in the human resources space—as a tool for companies to offer staff for on-demand, privacy-first mental health support. Back in Taiwan , the app already has hospitals, mental health clinics, universities, publicly listed companies, and government agencies that use it, similarly spurred by a shortage of mental health workers. About Bamboo Technology Established in November 2018 , the Taipei -based Bamboo Technology is a mental health technology innovation company that focuses on improving public mental health with voice emotion analysis technology. It embraces a belief that a universal, objective, and scientific mental health system can effectively solve the problem of deteriorating mental health in today's society — a core tenet upheld by its many psychologists; social workers; and information management, AI and big data experts. View original content to download multimedia: https://www.prnewswire.com/news-releases/bamboo-technologys-herehear-virtual-ai-therapist-joins-berkeley-skydeck-ipp-program-302325187.html SOURCE BAMBOO TECHNOLOGY LTD.
Cox Enterprises Nearing One-Third of its Ambitious Goal to Empower 34 Million People to Live More Prosperous Lives by 2034SGR-1505 is under clinical development by and currently in Phase I for Burkitt Lymphoma. According to GlobalData, Phase I drugs for Burkitt Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. SGR-1505 overview SGR-1505 is under development for the treatment of BTK-resistant, refractory or relapsed B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia, MALT lymphoma, follicular lymphoma, Burkitt lymphoma, plasmablastic lymphoma, high-grade B-cell lymphoma, primary cutaneous follicle center lymphoma, primary effusion lymphoma, primary mediastinal large B cell lymphoma, T-cell/histiocyte rich lymphoma, ALK-positive large B-cell lymphoma, primary cutaneous diffuse large B-cell lymphoma splenic marginal zone lymphoma, nodal marginal zone lymphoma, HHV8-positive DLBCL and duodenal-type follicular lymphoma. It is administered through oral route in the form of tablet. The drug candidate acts by oncogenic activation of nuclear factor-kappa B which acts by targeting MALT1 activity. It is developed based on the artificial intelligence (AI) technology. Schrodinger overview is a healthcare technology company that provides software solutions for drug discovery. The company offers a computational platform designed with predictive modeling, data analytics and collaboration applicable to molecular discovery. Its pipeline products include SGR-1505 (MALT1) against non-Hodgkin’s lymphoma, SGR-2921 (CDC7) to treat hematological cancers and solid tumors and SGR-3515 (Wee1) for gynecological cancers, and LRRK2 for Neurology and SOS1 for cancers and others. ‘s other products include small molecule products, biological drug discovery and material science products. It provides training, documentation and support services. The company operates through offices in the US, Germany, Japan, Ireland, the UK, India, China and South Korea. is headquartered in New York City, New York, the US. For a complete picture of SGR-1505’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .
‘Fill your home with festive scents’, cry Aldi Ireland bosses over €4.99 candle with long-lasting burnNone
- Previous:
- Next: esports world cup 2024 schedule